TRIM26 deficiency drives gastric cancer lymph node metastasis via TGF-β signaling activation and modulates gemcitabine response

TRIM26 inhibits LNM by modulating TGF-β signaling and remodeling the tumor microenvironment. Clinically, low TRIM26 expression identifies tumors with reduced sensitivity to gemcitabine, reflected by higher estimated IC₅₀ values-a correlation underpinned by computational models demonstrating stable drug binding. Thus, TRIM26 serves as a integrated prognostic and predictive biomarker, positioning it as a promising theranostic target to inform precision therapy strategies in GC.